IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Amgen Inc. (“Amgen” or the “Company”) (Nasdaq: AMGN) concerning possible violations of federal securities laws.
If you purchased shares of Amgen and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation focuses on whether Amgen and certain of its officers and/or directors violated federal securities laws. On May 22, 2017, the Company revealed that its osteoporosis medicine, Evenity, raised concerns about heart safety that will cause a delay in obtaining approval in the United States. According to data disclosed by Amgen, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, than those who took an older approved medicine.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.